Dermata Therapeutics Statistics

Total Valuation

DRMA has a market cap or net worth of $5.19 million. The enterprise value is -$1.76 million.

Market Cap	5.19M
Enterprise Value	-1.76M

Important Dates

The next estimated earnings date is Wednesday, August 12, 2026, after market close.

Earnings Date	Aug 12, 2026
Ex-Dividend Date	n/a

Share Statistics

DRMA has 4.02 million shares outstanding. The number of shares has increased by 550.83% in one year.

Current Share Class	4.02M
Shares Outstanding	4.02M
Shares Change (YoY)	+550.83%
Shares Change (QoQ)	+241.28%
Owned by Insiders (%)	21.01%
Owned by Institutions (%)	5.86%
Float	3.17M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	51.89
PB Ratio	0.81
P/TBV Ratio	0.81
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.09

Current Ratio	7.09
Quick Ratio	6.60
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -103.58% and return on invested capital (ROIC) is -67.09%.

Return on Equity (ROE)	-103.58%
Return on Assets (ROA)	-52.66%
Return on Invested Capital (ROIC)	-67.09%
Return on Capital Employed (ROCE)	-114.77%
Weighted Average Cost of Capital (WACC)	8.04%
Revenue Per Employee	n/a
Profits Per Employee	-$789,186
Employee Count	9
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -79.38% in the last 52 weeks. The beta is 0.69, so DRMA's price volatility has been lower than the market average.

Beta (5Y)	0.69
52-Week Price Change	-79.38%
50-Day Moving Average	1.26
200-Day Moving Average	2.34
Relative Strength Index (RSI)	54.04
Average Volume (20 Days)	71,390

Short Selling Information

The latest short interest is 96,498, so 2.40% of the outstanding shares have been sold short.

Short Interest	96,498
Short Previous Month	114,588
Short % of Shares Out	2.40%
Short % of Float	3.05%
Short Ratio (days to cover)	1.84

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-7.36M
Pretax Income	-7.10M
Net Income	-7.10M
EBITDA	n/a
EBIT	-7.36M
Earnings Per Share (EPS)	-$4.03

Full Income Statement

Balance Sheet

The company has $6.95 million in cash and n/a in debt, giving a net cash position of $6.95 million or $1.73 per share.

Cash & Cash Equivalents	6.95M
Total Debt	n/a
Net Cash	6.95M
Net Cash Per Share	$1.73
Equity (Book Value)	6.41M
Book Value Per Share	1.59
Working Capital	6.41M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-8.30M
Capital Expenditures	n/a
Depreciation & Amortization	n/a
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

DRMA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-550.83%
Shareholder Yield	-550.83%
Earnings Yield	-136.89%
FCF Yield	n/a

Analyst Forecast

The average price target for DRMA is $4.00, which is 210.08% higher than the current price. The consensus rating is "Buy".

Price Target	$4.00
Price Target Difference	210.08%
Analyst Consensus	Buy
Analyst Count	1
Revenue Growth Forecast (3Y)	n/a
EPS Growth Forecast (3Y)	n/a

Stock Splits

The last stock split was on August 1, 2025. It was a reverse split with a ratio of 1:10.

Last Split Date	Aug 1, 2025
Split Type	Reverse
Split Ratio	1:10

Scores

Altman Z-Score	n/a
Piotroski F-Score	1